Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients

Authors AlDallal SM

Received 20 April 2017

Accepted for publication 26 June 2017

Published 20 July 2017 Volume 2017:13 Pages 905—907

DOI https://doi.org/10.2147/TCRM.S140023

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Salma M AlDallal

Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait

Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody’s therapeutic effect on chronic lymphocytic leukemia.

Keywords: ofatumumab, cell-mediated cytotoxicity, chronic lymphocytic leukemia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]